Non Small Cell Lung Cancer (NSCLC)

Stage I-III: Unresectable

Stage I

LUN0071
Phase I/II
Folfiririmab &
Stereotactic
Ablative
Radiotherapy in
Early Stage
Non-Small Cell
Lung Cancer

PI: Diehn
Stanford

Treated w/SBRT
+/- adjuvant chemo

LUN015
Adjuvant
Durvalumab for
Early Stage
NSCLC Patients
with cDNA
Minimal Residual
Disease

PI: Neal
Stanford

NRGLU004
Phase I RT
Combined w/
MEDI4736
(Durvalumab) in
PD-L1 High
Locally Advanced
NSCLC

PI: Diehn
NRG

LUN0114
Personalized
Escalation of
Consolidation
Treatment After
ChemoRT &
Immunotherapy in
Stage IIB/III
NSCLC

PI: Neal
Stanford

Stage II-III

VAR0203
Performance and
Safety of
Biology-Guided
Radiotherapy
using the
RefleXion Medical
Radiotherapy
System

PI: Chang
Stanford

Stage I-IV

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold